Abstract:Pleckstrin-2 (Plek2) is a widely expressed PH domain containing protein that binds to phosphoinositide with unclear functions. Our published reports reveal that Plek2 is overexpressed in JAK2 V617F mutation positive myeloproliferative neoplasms (MPNs). We identified that Plek2 is a downstream effector of the JAK2-STAT5 pathway. Furthermore, through a mouse genetic approach, we discovered that knockout of Plek2 significantly ameliorated the MPN phenotypes and reverted lethality and thrombosis in JAK2 V617F knockin mice. These studies demonstrate that Plek2 is critical for the pathogenesis of MPNs with the activated JAK2-STAT5 pathway, and form a strong foundation for the development of Plek2 inhibitors for the treatment of MPNs. Importantly, our published study shows that Plek2 knockout mice do not develop anemia or cytopenia, indicating Plek2’s oncogenic potential is only in the disease background, which makes Plek2 inhibitors less likely to cause severe side effects compared to JAK inhibitor ruxolitinib. Based on these studies, we used an in silico approach to screen for putative Plek2 binding small molecules and identified hit compounds that bind to the DEP domain of Plek2. Further medicinal chemistry studies identified lead compound NUP-17d that inhibited proliferation of the hyperproliferative hematopoietic cells with potency comparable to ruxolitinib. In addition, NUP-17d also blocked proliferation of several Plek2-overexpressing solid tumor cell lines. Our biochemical assays showed that NUP-17d inhibited Akt phosphorylation. Further mechanistic studies revealed that Plek2 functions as a central hub to mediate the JAK2-STAT and PI3K-Akt pathways to promote tumor cell proliferation. Specifically, Plek2 binds to and recruits PI3K-produced PtdIns(3,4)P2 and PI3K effector proteins including Akt, PDK1, PDK2, and mTOR, which forms a complex and significantly enhances the PI3K signaling. In addition to the biochemical assays, we also demonstrated Plek2’s function through a mouse genetic approach using a Pten hematopoietic specific knockout mouse model. Knockout of Plek2 significantly reverted the myeloproliferative phenotype in these mice and markedly extended their survival. Therefore, NUP-17d blocks tumor cell proliferation through the disruption of the Plek2 complex and inhibition of the PI3K-Akt pathway. Indeed, treatment of an erythropoietin-induced myeloproliferative mouse model with NUP-17d also demonstrated its potent inhibitory effect in myeloproliferation in vivo. These study establishes Plek2 as a oncoprotein mediating JAK2-STAT and PI3K-Akt signaling pathways. In addition to hematologic malignancies, Plek2 is also found to be highly upregulated with an associated worse prognosis in many solid tumors (oncomine, kmplot). Therefore, our Plek2 inhibitors will have a broad impact in cancer therapy, especially cancers with upregulated JAK2-STAT or PI3K-Akt pathway. Citation Format: Xu Han, Yang Mei, Gary E. Schiltz, Rama K. Mishra, Atul D. Jain, Peng Ji. Targeting pleckstrin-2 for the JAK2-STAT and PI3K-Akt pathways in cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1287.

PLEK2 Promotes Osteosarcoma Tumorigenesis and Metastasis by Activating the PI3K/AKT Signaling Pathway

PLEK2 promotes migration and invasion in pancreatic ductal adenocarcinoma by MMP1 through IL-17 pathway

TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2

PLEK2 promotes lung adenocarcinoma progression via activating the PI3K/AKT signaling pathway through SPC25 Running title: PLEK2 promotes LUAD via SPC25/PI3K/AKT axis

PLEK2 activates the PI3K/AKT signaling pathway to drive lung adenocarcinoma progression by upregulating SPC25

LncCCAT1 Interaction Protein PKM2 Upregulates SREBP2 Phosphorylation to Promote Osteosarcoma Tumorigenesis by Enhancing the Warburg Effect and Lipogenesis.

Expression of PLEK2 in malignant tumors and its influence on invasion and metastasis

SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling.

Pleckstrin-2 Mediates the Activation of AKT in Prostate Cancer and is Repressed by Androgen Receptor

PLOD2 High Expression Associates with Immune Infiltration and Facilitates Cancer Progression in Osteosarcoma

PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loop

Pleckstrin-2 As a Prognostic Factor and Mediator of Gastric Cancer Progression.

Expression and prognostic potential of PLEK2 in head and neck squamous cell carcinoma based on bioinformatics analysis

Pleckstrin‐2‐promoted PPM1B Degradation Plays an Important Role in Transforming Growth Factor‐β‐induced Breast Cancer Cell Invasion and Metastasis

KCNJ2/HIF1α Positive-Feedback Loop Promotes the Metastasis of Osteosarcoma

Effect of activation of the Akt/mTOR signaling pathway by EEF1A2 on the biological behavior of osteosarcoma

Neuropilin and Tolloid-Like 2 Regulates the Progression of Osteosarcoma.

PLEK2 Mediates Metastasis and Vascular Invasion Via the Ubiquitin‐dependent Degradation of SHIP2 in Non‐small Cell Lung Cancer

MAT2B Promotes Proliferation and Inhibits Apoptosis in Osteosarcoma by Targeting Epidermal Growth Factor Receptor and Proliferating Cell Nuclear Antigen

Abstract 1287: Targeting Pleckstrin-2 for the JAK2-STAT and PI3K-Akt Pathways in Cancer Therapy

Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling